DARE Daré Bioscience, Inc.: מקדם חוב לטווח ארוך להון

Dare Bioscience, Inc. (DARE) generates revenue through the implementation of XACIATO and the development of long-term female contraceptives. The business model relies on outsourcing production and trials to minimize capital expenditures. The ratio of long-term liabilities to equity demonstrates the debt load dynamics, where the value of 0.00 reflects the metric's balance. Patent protection for hydrogels provides the company with a sustainable advantage in negotiations with partners.

Dare Bioscience, Inc. (DARE) invests in the development of unique non-hormonal women's health products. The long-term debt-to-equity ratio reflects the company's reliance on external borrowed financing. This coefficient measures the proportion of loans with a maturity exceeding one year relative to the market value of net assets. Analyzing the financial leverage indicator for long-term debt allows for an assessment of the risk of cash flow gaps. A low debt level confirms financial stability during the scaling of patented developments.